Search results for "cancer cells"

showing 10 items of 98 documents

Melatonin Targets Metabolism in Head and Neck Cancer Cells by Regulating Mitochondrial Structure and Function.

2021

This study was funded by grants from the Ministerio de Economia, Industria y Competitividad y por el Fondo de Desarrollo Regional FEDER, Spain nº SAF2013-49019, SAF2017-85903-P, and from the Consejería de Innovación, Ciencia y Empresa, Junta de Andalucía (P07- CTS- 03135, P10- CTS- 5784, and CTS- 101), Spain. J.F. and L.M. have FPU fellowships from the Ministerio de Educación Cultura y Deporte, Spain. C.R.S. was a schorlarship holder from the Plan Propio de Investigación of the University of Granada.

0301 basic medicine:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Phosphorylation::Oxidative Phosphorylation [Medical Subject Headings]PhysiologyClinical BiochemistrymelatoninMitochondrionBiochemistryMelatonina:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicine:Anatomy::Cells::Cells Cultured::Cell Line [Medical Subject Headings]head and neck cancer cells:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Drug Resistance Neoplasm [Medical Subject Headings]MitophagyMitocondriasChemistryapoptosisglycolysisOXPHOSmitochondria030220 oncology & carcinogenesishormones hormone substitutes and hormone antagonistsmedicine.drug:Phenomena and Processes::Chemical Phenomena::Biochemical Phenomena::Biochemical Processes::Carbohydrate Metabolism::Glycolysis [Medical Subject Headings]Neoplasias de cabeza y cuello:Diseases::Neoplasms::Neoplasms by Site::Head and Neck Neoplasms [Medical Subject Headings]:Chemicals and Drugs::Inorganic Chemicals::Free Radicals::Reactive Oxygen Species [Medical Subject Headings]Mitofagiafree radicalsOxidative phosphorylationArticleMelatonin03 medical and health sciencesmedicine:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Growth Processes::Cell Proliferation [Medical Subject Headings]Molecular BiologyRadicales libresCell growth:Chemicals and Drugs::Amino Acids Peptides and Proteins::Proteins::DNA-Binding Proteins::Receptors Cytoplasmic and Nuclear::Receptors Melatonin [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings]lcsh:RM1-950:Anatomy::Cells::Cellular Structures::Subcellular Fractions::Mitochondria [Medical Subject Headings]Cell Biologymedicine.diseaseHead and neck squamous-cell carcinoma:Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Death::Apoptosis [Medical Subject Headings]Glucólisis030104 developmental biologylcsh:Therapeutics. PharmacologymitophagyApoptosisCancer cellCancer research:Chemicals and Drugs::Hormones Hormone Substitutes and Hormone Antagonists::Hormones::Melatonin [Medical Subject Headings]
researchProduct

Extracellular vesicles as miRNA nano-shuttles : dual role in tumor progression

2018

[EN] Tumor-derived extracellular vesicles (EVs) have a pleiotropic role in cancer, interacting with target cells of the tumor microenvironment, such as fibroblasts, immune and endothelial cells. EVs can modulate tumor progression, angiogenic switch, metastasis, and immune escape. These vesicles are nano-shuttles containing a wide spectrum of miRNAs that contribute to tumor progression. MiRNAs contained in extracellular vesicles (EV-miRNAs) are disseminated in the extracellular space and are able to influence the expression of target genes with either tumor suppressor or oncogenic functions, depending on both parental and target cells. Metastatic cancer cells can balance their oncogenic pote…

0301 basic medicineCancer ResearchAngiogenic SwitchLung-CancerBIOLOGIA CELULARMessenger-RNAsSuppressor-CellsDendritic cellsMetastasisLiquid biopsies03 medical and health sciencesExtracellular VesiclesImmune systemSettore BIO/13 - Biologia ApplicatamicroRNAMedicineHumansNanotechnologyPharmacology (medical)miRNAMyelogenous Leukemia-CellsExtracellular vesicles; miRNA; cancer cellsTumor microenvironmentExosome-Mediated transferbusiness.industryCancerProteinsmedicine.diseaseMicrornasMicroRNAs030104 developmental biologyOncologyTumor progressionCancer cellcancer cellsCancer researchDisease ProgressionHuman medicineExtracellular vesiclebusinessMicrovesiclesTargeted oncology
researchProduct

Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2.

2017

Triple-negative breast cancer is a group of aggressive cancers with poor prognosis owing to chemoresistance, recurrence and metastasis. New strategies are required that could reduce chemoresistance and increases the effectiveness of chemotherapy. The results presented in this paper, showing that parthenolide (PN) prevents drug resistance in MDA-MB231 cells, represent a contribution to one of these possible strategies. MDA-MB231 cells, the most studied line of TNBC cells, were submitted to selection treatment with mitoxantrone (Mitox) and doxorubicin (DOX). The presence of resistant cells was confirmed through the measurement of the resistance index. Cells submitted to this treatment exhibit…

0301 basic medicineCancer ResearchSmall interfering RNATriple-negative breast cancer resistance parthenolideImmunologyStimulationCancer -- TreatmentArticle03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compound0302 clinical medicineDownregulation and upregulationSettore BIO/10 - BiochimicamedicineChemotherapyDoxorubicinParthenolideBreast -- CancerDrug resistance in cancer cellsMitoxantroneChemistryCell BiologyTransfectionHsp70030104 developmental biology030220 oncology & carcinogenesisCancer researchmedicine.drugCell death discovery
researchProduct

Physiological concentrations of phytosterols enhance the apoptotic effects of 5-fluorouracil in colon cancer cells

2018

Abstract Combining natural products as co-adjuvants in 5-fluorouracil (5-FU) chemotherapy might enhance the effectiveness of 5-FU by avoiding a high dosage and/or reducing treatment times. We explored the anticancer efficacy of the phytosterols (PS) at concentrations achievable in the human colon, as well as their potential as sensitizing agents of human colon cancer cells (Caco-2 and HT-29) to 5-FU treatment. Cells proliferation, combination index, cell cycle, apoptosis, caspases activation, ROS production, and ΔΨm were determined. Co-treatment (PS+5-FU) had an antiproliferative additive effect, and moreover, in general a significantly improved efficacy was observed on cell cycle arrest at…

0301 basic medicineCell cycle checkpointColorectal cancermedicine.medical_treatmentMedicine (miscellaneous)ApoptosisCell cycle03 medical and health sciences0302 clinical medicineIn vivomedicine5-fluorouracilTX341-641Colon cancer cellsCaspaseChemotherapyNutrition and DieteticsbiologyNutrition. Foods and food supplyChemistryPhytosterolsCell cyclemedicine.disease030104 developmental biologyApoptosisFluorouracil030220 oncology & carcinogenesisCancer researchbiology.proteinDrug sensitivityFood Sciencemedicine.drugJournal of Functional Foods
researchProduct

In Vitro Study of the Cytotoxic, Cytostatic, and Antigenotoxic Profile of Hemidesmus indicus (L.) R.Br. (Apocynaceae) Crude Drug Extract on T Lymphob…

2018

In traditional Indian medicine, the crude drug Hemidesmus indicus root—commonly known as Indian sarsaparilla—is used alone or in poly-herbal preparations for the treatment of a wide range of diseases. The present study focuses on the cancer chemopreventive and therapeutic potential of H. indicus extracts on an acute lymphoblastic leukemia cell line (CCRF-CEM). With this aim in mind, we subjected H. indicus roots to two subsequent extractions (hydro-alcoholic extraction and soxhlet extraction). As DNA damage is an important prerequisite for the induction of mutations/cancer by genotoxic carcinogens, cancer chemoprevention may be achieved by preventing genotoxicity. Through an integrated …

0301 basic medicineDNA damageCell SurvivalHealth Toxicology and MutagenesisPhytochemicalsHemidesmus indicus; cancer cells; apoptosis; cell cycle; genotoxicity; antigenotoxicityantigenotoxicitylcsh:MedicineCancer cellCrude drugPharmacologymedicine.disease_causeToxicologyProtective AgentsPlant RootsArticleNOHemidesmus indicus03 medical and health sciences0302 clinical medicineCell Line TumormedicineHumansCarcinogenHemidesmus indicusHemidesmusbiologyChemistryPlant Extractslcsh:RgenotoxicityapoptosisApoptosiHemidesmus indicuCell cyclePrecursor Cell Lymphoblastic Leukemia-Lymphomabiology.organism_classificationAntineoplastic Agents Phytogenic030104 developmental biologyApoptosis030220 oncology & carcinogenesisCancer cellcancer cellscell cycleGenotoxicity<i>Hemidesmus indicus</i>; cancer cells; apoptosis; cell cycle; genotoxicity; antigenotoxicityDNA DamageToxins
researchProduct

N-(2-methyl-indol-1H-5-yl)-1-naphthalenesulfonamide : a novel reversible antimitotic agent inhibiting cancer cell motility

2016

Este es el post-print que se ha publicado de forma definitiva en: https://www.sciencedirect.com/science/article/abs/pii/S0006295216301423 A series of compounds containing the sulfonamide scaffold were synthesized and screened for their in vitro anticancer activity against a representative panel of human cancer cell lines, leading to the identification of N-(2-methyl-1H-indol-5-yl)-1-naphthalenesulfonamide (8e) as a compound showing a remarkable activity across the panel, with IC50 values in the nanomolar-to-low micromolar range. Cell cycle distribution analysis revealed that 8e promoted a severe G2/M arrest, which was followed by cellular senescence as indicated by the detection of senescen…

0301 basic medicineIndolesSulfonamides - Therapeutic use.MotilityApoptosisAntimitotic AgentsMicrotubulesBiochemistryJurkat Cells03 medical and health sciences0302 clinical medicineCell MovementTubulinMicrotubuleCélulas cancerosas - Motilidad.Apoptosis.HumansSulfamidas - Uso terapéutico.MitosisCell ProliferationPharmacologySulfonamidesMolecular StructurebiologyCancer cells - Motility.Cell cycleCell biologyMitosis.030104 developmental biologyTubulinCell cultureApoptosis030220 oncology & carcinogenesisCancer cellMCF-7 Cellsbiology.proteinDrug Screening Assays AntitumorDNA Damage
researchProduct

LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis

2016

International audience; Blastic plasmacytoid dendritic cell (PDC) neoplasm (BPDCN) is an aggressive hematological malignancy with a poor prognosis that derives from PDCs. No consensus for optimal treatment modalities is available today and the full characterization of this leukemia is still emerging. We identified here a BPDCN-specific transcriptomic profile when compared with those of acute myeloid leukemia and T-acute lymphoblastic leukemia, as well as the transcriptomic signature of primary PDCs. This BPDCN gene signature identified a dysregulation of genes involved in cholesterol homeostasis, some of them being liver X receptor (LXR) target genes. LXR agonist treatment of primary BPDCN …

0301 basic medicineMaleCellProliferationApoptosisExpressionPlasmacytoid dendritic cellPrecursor T-Cell Lymphoblastic Leukemia-LymphomaBiochemistryMice0302 clinical medicinepolycyclic compoundsSTAT5 Transcription Factor[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyATP Binding Cassette Transporter Subfamily G Member 1Liver X ReceptorsInhibitionMyeloid NeoplasiabiologyMyeloid leukemiafood and beveragesMyeloid-Leukemia[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyInterleukin-3 Receptor3. Good healthLeukemiamedicine.anatomical_structureCholesterol030220 oncology & carcinogenesisFemalelipids (amino acids peptides and proteins)In-VivoATP Binding Cassette Transporter 1ImmunologyActivationAntineoplastic Agentsdigestive system03 medical and health sciencesCell Line TumormedicineAnimalsHumansLiver X receptorProtein kinase BCell ProliferationCell growthCell BiologyDendritic Cellsmedicine.diseaseXenograft Model Antitumor Assays030104 developmental biologyProstate-Cancer CellsABCA1biology.proteinCancer researchDensity-Lipoprotein ReceptorInterleukin-3Proto-Oncogene Proteins c-akt
researchProduct

When Three Isn't a Crowd: A Digyny Concept for Treatment-Resistant, Near-Triploid Human Cancers.

2019

Near-triploid human tumors are frequently resistant to radio/chemotherapy through mechanisms that are unclear. We recently reported a tight association of male tumor triploidy with XXY karyotypes based on a meta-analysis of 15 tumor cohorts extracted from the Mitelman database. Here we provide a conceptual framework of the digyny-like origin of this karyotype based on the germline features of malignant tumors and adaptive capacity of digyny, which supports survival in adverse conditions. Studying how the recombinatorial reproduction via diploidy can be executed in primary cancer samples and HeLa cells after DNA damage, we report the first evidence that diploid and triploid cell sub-populati…

0301 basic medicineMalelcsh:QH426-470DNA repairKaryotypeSpindle ApparatusDigynyBiologyGenomeGermline03 medical and health sciencesnear-triploid cancer0302 clinical medicineMeiosisNeoplasmsGeneticsTumor Cells Culturedtumor blastomeresHumansGeneGenetics (clinical)GeneticsChromosomes Human XChromosomes Human YModels Geneticfungifood and beverageschemoresistancereprogrammingKaryotypeConcept Papertripolar mitosisTriploidyradioresistancelcsh:GeneticsMeiosis030104 developmental biologyGerm Cellspedogamy030220 oncology & carcinogenesisNeoplastic Stem Cellspolynuclear cancer cellsPloidyHeLa CellsdigynyGenes
researchProduct

Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization

2020

Simple Summary Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome is a very rare hereditary disorder characterized by cutaneous leiomyomas (CLMs), uterine leiomyomas (ULMs), renal cysts (RCys) and renal cell cancer (RCC), with no data on its prevalence worldwide. No genotype-phenotype associations have been described. The aim of our study was to describe the genotypic and phenotypic features of the largest series of patients with HLRCC from Spain reported to date. Of 27 FH germline pathogenic variants, 12 were not previously reported in databases. Patients with missense pathogenic variants showed higher frequencies of CLMs, ULMs and RCys, than those with loss-of-function varia…

0301 basic medicineOncologyCancer ResearchCancer cellsmedicine.disease_causeurologic and male genital diseases:Male Urogenital Diseases::Urogenital Neoplasms::Urologic Neoplasms::Kidney Neoplasms::Male Urogenital Diseases::Carcinoma Renal Cell [DISEASES]<i>FH</i> gene0302 clinical medicineMalalties hereditàriesMissense mutationFH geneFH gene hereditary leiomyomatosis leiomyomas missense pathogenic variants renal cell cancerRenal cell cancerMutationKidney diseasesHereditary leiomyomatosis:Otros calificadores::Otros calificadores::/genética [Otros calificadores]:enfermedades urogenitales masculinas::neoplasias urogenitales::neoplasias urológicas::neoplasias renales::enfermedades urogenitales masculinas::carcinoma de células renales [ENFERMEDADES]leiomyomasmissense pathogenic variants renal cell cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRare diseases:Geographic Locations::Europe::Spain [GEOGRAPHICALS]Oncology030220 oncology & carcinogenesisCohortCèl·lules cancerosesMalalties raresRenal Cell CancersGenetic disordersmedicine.medical_specialtyMissense pathogenic variantsBiología Celularlcsh:RC254-282Article03 medical and health sciencesLeiomyomasInternal medicine:Other subheadings::Other subheadings::/genetics [Other subheadings]medicineRonyons - Malalties - Espanya:localizaciones geográficas::Europa (continente)::España [DENOMINACIONES GEOGRÁFICAS]business.industry:neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::leiomioma::leiomiomatosis [ENFERMEDADES]Retrospective cohort studymedicine.diseaseGenética030104 developmental biologyFumaraseClinical diagnosisHereditary leiomyomatosis and renal cell cancer syndromeMalalties del ronyó:Neoplasms::Neoplasms by Histologic Type::Neoplasms Connective and Soft Tissue::Neoplasms Muscle Tissue::Leiomyoma::Leiomyomatosis [DISEASES]hereditary leiomyomatosisbusiness
researchProduct

Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin

2017

// Sergio Rizzo 1, * , Antonina Cangemi 1, * , Antonio Galvano 1, * , Daniele Fanale 1 , Silvio Buscemi 2 , Marcello Ciaccio 3 , Antonio Russo 1 , Sergio Castorina 4, 5, # and Viviana Bazan 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Department of Internal and Specialistic Medicine (DIBIMIS), Laboratory of Clinical Nutrition, University of Palermo, Palermo, Italy 3 Section of Clinical Biochemistry and Clinical Molecular Medicine, Department of Biopathology and Medical Biotechnology, University of Palermo, U.O.C. Laboratory Medicine, Policlinico University Hospital, Palermo, Italy 4 Fondazione Mediterranea…

0301 basic medicineOncologymedicine.medical_specialtychemotherapy responseClinical nutritiondoxorubicin03 medical and health sciences0302 clinical medicineInternal medicinemicroRNAmedicineDoxorubicinTriple-negative breast cancershort term starvationtriple negative breast cancer cellsbusiness.industryCancerMicroRNAmedicine.diseaseMolecular medicinemicroRNAstriple negative breast cancer cell030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisImmunologyBreast cancer cellsbusinessChemotherapy response; Doxorubicin; MicroRNAs; Short term starvation; triple negative breast cancer cells; Oncologymedicine.drugResearch PaperOncotarget
researchProduct